AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
FDA Investigating Hypersensitivity Reports Tied to IGIV Lot
October 07, 2026
FDA Seeks Nominations for Federal Advisory Committee Members, Including BPAC and CTGTAC
October 06, 2026
FDA Updates Biological Product Deviation Reporting Codes
October 05, 2026
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
